Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
LAMOTRIGINE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | USP36–NF31 | 4056 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Standard solution: Change 0.028 µg/mL to: 0.028 mg/mL |
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 5438 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More |
PURIFIED GYMNEMA EXTRACT | COMPOSITION/Content of Gymnemic Acids | First Supplement to USP36–NF31 | 5884 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Acceptance criteria: Change 90%–110% of the labeled amount to: 90.0%–110.0% of the labeled amount on the dried basis |
SODIUM HYDROXIDE | ASSAY/Procedure | USP36–NF31 | 2203 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change = volume of Titrant consumed by the Sample to the first endpoint (mL) to: = volume of Titrant consumed by the Sample to the second endpoint (mL) |
CLARITHROMYCIN FOR ORAL SUSPENSION | ASSAY/Procedure | USP36–NF31 | 3018 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Change the subsection head Buffer: to: Buffer A: AND After the Buffer A subsection: Add Buffer B: 0.067 M dibasic potassium phosphate AND Line 1 of Mobile phase: Change Methanol and Buffer to: Methanol and Buffer A… Read More |
PENTAZOCINE INJECTION | Chemical Information | USP36–NF31 | 4734 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Remove all chemical information. |
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES | Assay | USP36–NF31 | 4838 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. … Read More |
SELEGILINE HYDROCHLORIDE TABLETS | Dissolution <711> | USP36–NF31 | 5120 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Chromatographic system: Change Chromatograph the Standard solution, and record the peak responses. to: The flow rate is 1.0 mL/min. Chromatograph the Standard solution, and record the peak responses. |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS | METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES | USP36–NF31 | 619 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Change the section title Method 6—Postcolumn DABS-CI Derivatization General Principle to: Method 6—Precolumn DABS-CI Derivatization General Principle |
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION | Assay | USP36–NF31 | 5558 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Mobile phase: Change 0.01 M to: 0.01 N AND Line 7 of Assay preparation: Change 10-mL to: 100-mL |
AMITRIPTYLINE HYDROCHLORIDE TABLETS | IDENTIFICATION/A. | USP36–NF31 | 2464 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Sample solution: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: Sample stock solution: Nominally 0.1 mg/mL of… Read More |
MINOCYCLINE FOR INJECTION | Assay | USP36–NF31 | 4375 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More |
OXYCODONE AND ACETAMINOPHEN TABLETS | IDENTIFICATION/A. Thin-Layer Chromatography | USP36–NF31 | 4645 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Sample solution: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1). |
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4834 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS | Assay | USP36–NF31 | 4841 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 5: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— Line 1 of Procedure: Change in the Assay under Potassium Chloride Oral Solution. to: for Instrumental… Read More |
ISOTRETINOIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 4 | Revision Bulletin (Official October 01, 2012) | Online | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Medium: Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of lauryl dimethyl amine oxide |
TROLAMINE SALICYLATE | Assay | USP36–NF31 | 5499 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Chromatographic system: Change L1 to: L7 |
NITRIC ACID | ASSAY/Procedure | USP36–NF31 | 2107 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample solution: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water. |
FOSPHENYTOIN SODIUM INJECTION | Assay | USP36–NF31 | 3680 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Assay preparation: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium, |
MOXIFLOXACIN OPHTHALMIC SOLUTION | Assay | USP36–NF31 | 4414 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 4 of Resolution solution: Change 0.1 mg per mg and 0.001 mg per mg, to: 0.1 mg per mL and 0.001 mg per mL, |
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay | USP36–NF31 | 4833 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
POTASSIUM CHLORIDE FOR ORAL SOLUTION | Assay | USP36–NF31 | 4840 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
TACROLIMUS CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5257 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 11 of USP Tacrolimus System Suitability Mixture RS: Change
and tacrolimus 8-propyl analog (3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,… Read More |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS | APPENDIX | USP36–NF31 | 619 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Change the section title Method 6—Postcolumn DABS-CI Derivatization to: Method 6—Precolumn DABS-CI Derivatization |
VITAMIN E | SPECIFIC TESTS/Acidity | USP36–NF31 | 5579 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample: Change 40 mg to: 1.0 g |
FOSPHENYTOIN SODIUM | USP Reference standards <11> | USP36–NF31 | 3679 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 6: Change C14H15NO2 to: C14H13NO2 |
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION | Assay | USP36–NF31 | 4376 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180… Read More |
OXYCODONE TEREPHTHALATE | ASSAY/Procedure | USP36–NF31 | 4648 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 7 of Analysis: Change RU = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the Standard solution RS = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the … Read More |
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES | Dissolution <711> | USP36–NF31 | 4838 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 5: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 7 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
POTASSIUM CHLORIDE, POTASSIUM BICARBONATE, AND POTASSIUM CITRATE EFFERVESCENT TABLETS FOR ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4843 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. … Read More |
<228> ETHYLENE OXIDE AND DIOXANE | Method II | USP36–NF31 | 148 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 31 of Analysis: Change rS = ethylene oxide peak responses from Standard solution B to: rS = dioxane peak responses from Standard solution B |
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION | Assay | USP36–NF31 | 5558 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Sodium acetate solution: Change 0.01 M to: 0.01 N AND Line 6 of Assay preparation: Change 10-mL to: 100-mL |
ALBUTEROL SULFATE | Chromatographic purity | USP36–NF31 | 2352 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution. to… Read More |
MINOCYCLINE HYDROCHLORIDE CAPSULES | Assay | USP36–NF31 | 4375 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More |
NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP36–NF31 | 4509 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Solution A: Change Dissolve 330.9 mg of sodium phosphate to: Dissolve 330.9 g of dibasic sodium phosphate |
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4834 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS | Dissolution <711> | USP36–NF31 | 4841 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 5: Change Potassium stock solution— to: Standard stock solution— AND Line 7: Change Prepare as directed for Standard preparations to: Prepare as directed for Standard solutions AND Line 7 of Procedure: Change for … Read More |
THIMEROSAL TOPICAL AEROSOL | SPECIFIC TESTS/Alcohol Determination, Method II <611> | USP36–NF31 | 5369 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 4 of Analysis: Change Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: … Read More |
CARAWAY OIL | DEFINITION | USP36–NF31 | 1924 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3: Change It contains NMT 50.0% of d-carvone (C10H14O). to: It contains NLT 50.0% of d-carvone (C10H14O). |
NORTRIPTYLINE HYDROCHLORIDE | IMPURITIES/Organic Impurities | First Supplement to USP36–NF31 | 6027 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Acceptance criteria: Change Standard solution to: Sample solution |
FOSPHENYTOIN SODIUM INJECTION | USP Reference standards <11> | USP36–NF31 | 3680 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 6: Change C14H15NO2 to: C14H13NO2 |
MINOCYCLINE HYDROCHLORIDE TABLETS | Assay | USP36–NF31 | 4378 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More |
HYDROGENATED POLYDECENE | ASSAY/Content of Decene Oligomer | USP36–NF31 | 2133 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 3 of System suitability: Change [Note—The retention time for squalene is about 18 min; the relative retention times for tetradecane, hexadecane, and squalene are about 0.5, 0.6, and 1.0, respectively.] to: [Note—The retention time for squalane is about 18 min; the relative… Read More |
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM | ASSAY/Procedure | USP36–NF31 | 3075 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Betamethasone dipropionate stock solution: Change J being the ratio (in mg/g) of betamethasone to clotrimazole in the Cream to: J being the ratio of the labeled amount of betamethasone (in mg/g) to the labeled amount of clotrimazole (in mg/g) in the Cream |
CALCIUM SULFATE | SPECIFIC TESTS/Loss on Drying <731> | USP35–NF30 | 1724 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Acceptance criteria: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate |
TAPIOCA STARCH | Limit of oxidizing substances | USP35–NF30 | 1987 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 8: Change Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodide color. to: Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodine color. |
LEVETIRACETAM | ADDITIONAL REQUIREMENTS | USP35–NF30 | 3659 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 9 of USP Reference Standards <11>: Change
C8H14ClNO3 207.65 to: C8H15ClN2O2 206.67 |
DULOXETINE DELAYED-RELEASE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Chromatographic system | Second Supplement to USP35–NF30 | 5940 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Column: Change 4.6-mm x 7.5-cm; 3-µm packing L7 to: 4.6-mm x 7.5-cm; 3- or 3.5-µm packing L7 |
HYMETELLOSE | IMPURITIES/Chloride and Sulfate, Chloride <221> | USP36–NF31 | 2044 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Change the subsection title Standard solution to: Control solution AND Line 4 of Analysis: Change Standard solution to: Control solution AND Line 2 of Acceptance criteria: Change Standard solution to: … Read More |
BENZTROPINE MESYLATE | CHEMICAL INFORMATION | USP36–NF31 | 2628 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-, endo-, methanesulfonate; to: 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-N-methyl-, endo-, methanesulfonate; |